PEAK6
GPCR icon

PEAK6’s Structure Therapeutics GPCR Stock Holding History

PEAK6’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$292K Sell
6,055
-1,900
-24% -$130K ﹤0.01% 2159
2025
Q4 		$553K Sell
7,955
-3,045
-28% -$124K ﹤0.01% 2049
2025
Q3 		$308K Buy
11,000
+1,555
+16% +$31K ﹤0.01% 2325
2025
Q2 		$196K Hold
9,445
– – ﹤0.01% 2458
2025
Q1 		$163K Hold
9,445
– – ﹤0.01% 2495
2024
Q4 		$256K Buy
+9,445
New +$335K ﹤0.01% 2457

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PEAK6's GPCR Position: Q1 2026 in Review

PEAK6 reduced its Structure Therapeutics (GPCR) stake by 24% in Q1 2026, selling an estimated $130K and leaving 6,055 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #2159.

PEAK6 first reported a position in GPCR in Q4 2024 and has held it in 6 quarters since. The position peaked at $553K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • PEAK6 held 6,055 shares of Structure Therapeutics worth $292K as of Q1 2026.
  • PEAK6 sold 1,900 Structure Therapeutics shares in Q1 2026, an estimated $130K.
  • Structure Therapeutics made up ﹤0.01% of PEAK6's portfolio in Q1 2026, its #2159 holding.
  • PEAK6 first reported a position in Structure Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • PEAK6's Structure Therapeutics position peaked at $553K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.